Arthneeti
Lasa SupergeneriQ2 FY18

Lasa Supergeneri Q2 FY18 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹6.2Market Cap: ₹33 CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3
  • Lasa Supergenerics foresees a year-on-year growth of around 22% to 25% in sales/revenue.
  • Growth beyond this range is uncertain and may depend on acquisitions or new business opportunities.
  • The company aims to maintain current margins, though raw material price fluctuations may impact profitability.
  • Backward integration through new units (Unit-IV and upcoming Unit-V) is expected to improve profits in the near future.
  • Incremental turnover from new units (Unit-V) is anticipated starting FY19.
  • Business is driven by tender programs (especially monsoon season) with generally stable quarter-to-quarter sales.
  • Expansion into formulation business is considered a future opportunity but will start modestly post debt reduction and further planning.

See what Lasa Supergeneri management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • No explicit mention of any new fundraising through debt or equity in the current discussion.
  • The company’s priority is reducing existing debt rather than raising new debt; current debt stands at ~68 crores, including short and long-term.
  • Omkar Herlekar mentioned having personally lent 14 crores to the company.
  • No plans disclosed for immediate brand building or equity raising related to formulations.
  • CAPEX is ongoing for capacity expansion, but no mention of raising capital specifically for it.
  • Focus is on internal accruals and prudent financial management rather than fresh fundraising at present.

See what Lasa Supergeneri management said on order book — free account, 30 seconds.

Capex plans

Yes
- Capex is ongoing and essential for the company’s operations; without it, the company cannot run (Page 11). - The CAPEX turnover ratio is approximately 1:1 for greenfield expansions and about 3.5 times for brownfield expansions (additional equipment) (Page 11). - Unit IV (formerly Unit V) has been commissioned and production has started; trial runs are finishing, and commercial production will commence soon (Pages 13-14). - Incremental turnover from new units, like Unit V, is expected primarily from next financial year FY19 onwards (Page 16). - The company plans to continue capitalizing CWIP (Capital Work in Progress) year on year as new assets become operational (Page 14). - Forward integration into formulations is planned but timelines are uncertain, with priority currently on debt reduction before major expansion (Page 13). - Omkar Herlekar has lent Rs. 14 crores as loans to the company, indicating internal financial support for operations (Page 11). Overall, ongoing and future capex is planned with focus on expanding production capacity and integrating forward into formulations, while managing debt carefully.

Track Lasa Supergeneri — get its next earnings analysis in your feed

Margin guidance

Category 3
  • The company foresees a growth rate of 22% to 25% year-on-year.
  • Growth is considered modest and sustainable.
  • Any growth beyond this range may depend on acquisitions or new business opportunities.
  • Margins are expected to remain stable, though impacted by raw material price fluctuations.
  • Petrochemical price rises have caused temporary margin pressure; normalization is expected.
  • EBITDA is not affected by depreciation; PBT impacted by higher depreciation due to new CAPEX.
  • Depreciation run-rate of around Rs. 6 crores per quarter is expected to continue.
  • The company prioritizes debt reduction, improving financial health to support growth.
  • Formulation business margins are expected at 10%-12% EBITDA, with scalability benefits.
  • Entry into formulations is planned as forward integration, timelines not yet decided.

Order book

The transcript from the provided pages of the Lasa Supergenerics Limited earnings call does not explicitly mention details about the current or expected order book or pending orders. However, relevant points include: - The company is focusing on growth with a targeted year-on-year increase of 22%-25%. - There is optimism about improved profits in the second half due to backward integration (Unit-IV and upcoming Unit-V). - Export contributes about 40% of total sales. - The company is gradually moving towards formulations as a forward integration but has not yet entered this space. - Growth depends on acquisitions and new business opportunities but no specific order book figures or backlog orders are discussed. Therefore, no explicit information about specific order book size or pending orders is available in the provided transcript.

How does Lasa Supergeneri rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisLasa Supergeneri
Rev 3Mar 3
See where Lasa Supergeneri sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Lasa Supergeneri rank in Pharmaceuticals & Biotechnology?

Compare Lasa Supergeneri against every Pharmaceuticals & Biotechnology company (Q2 FY18) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Continue your research

What Lasa Supergeneri's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • IOL Chemicals (Q1 FY27)

    Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…

  • Innova Captab Ltd (Q1 FY27)

    The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…

  • Glenmark Pharma. (Q1 FY27)

    Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…

  • Strides Pharma Science Ltd (Q1 FY27)

    markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…

Compare:vs Sun Pharmaceutical Industries Ltdvs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →